Notwithstanding promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from pharmacy benefit managers. These insurers are frequently building barriers to access, like steep cost requirements